Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #2899 on Phio Pharmaceuticals Corp (PHIO)
InternetForumUser
10/15/15 11:05 AM
#2913 RE: The Other Guy #2899
Overall, the RXI-109 treated revision sites were scored statistically significantly better than the untreated revision sites in all four evaluations. Both dose levels of RXI-109 were equally well tolerated with occasional transient redness and itching occurring in both dose levels. Moreover, the higher dose of 10 mg/cm did not appear to add clinical benefit over the 5 mg/cm dose, leading to the conclusion that the next cohorts in this ongoing RXI-109-1402 study will be treated with the 5 mg/cm dose. These subsequent cohorts will include evaluation of additional treatments through six months to further define the optimum treatment regimen.